ASTRAZENECA PLC vs Novartis AG, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where AZN and NVS diverge most: on debt / equity, AZN reads 0.57 and NVS reads 0.02; on return on invested capital, AZN reads 14.8% and NVS reads 31.8%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | AZN | NVS |
|---|---|---|
| Price | $159.18 | $143.71 |
| Market cap | $246.7B | $278.7B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +0.5% |
| P/E | 24.1 | 19.9 |
| P/B | 5.06 | 5.99 |
| P/S | 4.20 | 5.11 |
| EV/EBITDA | 14.3 | 14.4 |
| Revenue growth | +12.1% | +6.4% |
| Gross margin | 81.9% | 78.8% |
| Operating margin | 23.4% | 32.4% |
| Net margin | 17.4% | 25.6% |
| Return on equity | 21.0% | 30.0% |
| Return on assets | 9.0% | 12.6% |
| Return on invested capital | 14.8% | 31.8% |
| FCF yield | 4.8% | 6.3% |
| Debt / equity | 0.57 | 0.02 |
| Current ratio | 0.94 | 1.12 |
| Altman Z (solvency) | 3.29 | 3.65 |
| Piotroski F (quality) | 8 / 9 | 8 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.